A trial of the PROphet blood test from Israel’s OncoHost (see here previously) has proved its accuracy and reliability in predicting the best treatment for metastatic non-small cell lung cancer (NSCLC) patients. OncoHost has received orders from 29 US cancer centers since its 2023 launch.

https://www.prnewswire.com/il/news-releases/journal-of-pharmaceutical–biomedical-analysis-publishes-study-analytically-validating-oncohosts-prophet-test-as-a-decision-support-tool-for-metastatic-nsclc-patients-301964509.html

https://www.sciencedirect.com/science/article/pii/S0731708523005721